Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Radius, 3M Drug Delivery Systems Announce Exclusive Agreement

Published: Friday, December 28, 2012
Last Updated: Thursday, December 27, 2012
Bookmark and Share
Partnership agreement for development, commercialization of transdermal delivery of BA058 for Osteoporosis.

Radius Health, Inc. and 3M Drug Delivery Systems have announced an exclusive partnership agreement for development and commercialization of BA058-transdermal (TD).

BA058 is a novel, synthetic proprietary peptide analog of human parathyroid hormone related protein or “hPTHrP,” a bone building anabolic compound with the potential to treat patients with osteoporosis at high risk of fracture.

This agreement updates the general development agreement announced in May 2011 by the two companies for BA058-TD.

BA058-transdermal (TD) is being studied in a Phase 2 clinical trial in healthy postmenopausal women with osteoporosis at 10 clinical centers.

BA058-TD is a short-wear time patch based on 3M's patented Microstructured Transdermal System technology.

The transdermal patch is expected to combine ease of use, convenience and self-administration attributes of a patch with the bone building efficacy of the BA058 compound.

“We are excited that 3M Drug Delivery Systems, which has long demonstrated a commitment to quality, safety and innovation, is partnering with us to bring a novel approach of drug delivery to the underserved osteoporosis patient population,” said Michael Wyzga, Radius president and chief executive officer.

Wyzga continued, “Our study data for BA058-TD showed that a five-minute wear time of the patch delivers peak drug levels consistent with subcutaneous injection and we hope to see increased patient compliance with 3M’s innovative technology.”

3M Drug Delivery Systems has partnered with pharmaceutical companies worldwide for more than 50 years, providing customized solutions to drug delivery.

“We are pleased to be part of Radius’ mission of advancing therapeutics for healthy aging with its deep expertise in osteoporosis,” said Ingrid Blair, MTS/TDD business vice president of 3M Drug Delivery Systems.

Blair continued, “With this exclusive agreement, 3M and Radius demonstrate our commitment to this innovative therapeutic treatment and this unique drug delivery mechanism. We believe this new drug potentially will improve the health of patients with severe osteoporosis and that 3M’s microneedle patch technology may improve medication compliance among patients.”

BA058 is also being studied as a daily subcutaneous injection (BA058-SC) in a Phase 3 study with 2,400 patients for fracture prevention in women with postmenopausal osteoporosis at high risk of fracture.

Phase 2 human testing of the injectable BA058-SC showed that BA058 significantly increased bone mineral density (BMD) at the lumbar spine and femoral neck (a common osteoporotic fracture site located in the hip joint) after six months of therapy.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Drug to Treat Alcohol Use Disorder Shows Promise Among Drinkers With High Stress
The findings suggest that potential future studies with drugs targeting vasopressin blockade should focus on populations of people with AUD who also report high levels of stress.
Scientists Find Lethal Vulnerability in Treatment-Resistant Lung Cancer
The study describes how the drug Selinexor killed lung cancer cells and shrank tumors in mice when used against cancers driven by the aggressive and difficult-to-treat KRAS cancer gene.
Advanced Lymphoma in Remission After T-Cell Therapy
63% of trial participants who recieved two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission.
New Treatment for Immune Cancers
Clinical trial shows new drug holds promise for treating advanced mastocytosis.
Sickle Cell Gene Therapy Passes Test
Researchers found a precision-engineered gene therapy virus reduced sickle-induced red-cell damage in mice with sickle cell disease.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Vitamin C May Boost Leukemia Treatment
Studies show that supplementing an epigenetic cancer drug with vitamin C enhanced the drug's effectiveness.
Inovio Launches Zika Vaccine Trial
Inovio launches Zika vaccine trial in midst of Puerto Rico epidemic to explore early signals of vaccine efficacy.
New Hope for Zika Treatment Found in Large-Scale Screen of Existing Drugs
Johns Hopkins researchers join collaborative group to screen 6,000 existing drugs in hopes of finding treatments for Zika Virus infection
FINCH Filgotinib Phase 3 Program Initiated
Galapagos NV reports the initiation of the FINCH global Phase 3 program in rheumatoid arthritis patient populations.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!